Last updated: May 17, 2024
Sponsor: Boston VA Research Institute, Inc.
Overall Status: Active - Recruiting
Phase
N/A
Condition
Tourette's Syndrome
Psychosis
Tinnitus
Treatment
sham-rt-fMRI-Neurofeedback
stg-rt-fMRI-Neurofeeback
Clinical Study ID
NCT05299749
4R33MH113751-03
Ages 18-55 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
patients diagnosed with SZ or schizoaffective disorder using DSM-5 criteria
auditory hallucinations not responsive to pharmacology as determined by chart reviewand a clinical interview of SCID.
Exclusion
Exclusion Criteria:
neurologic illness
major head trauma
electroconvulsive therapy
alcohol or drug dependence
alcohol or drug abuse within the past five years
verbal IQ below 70
Study Design
Total Participants: 104
Treatment Group(s): 2
Primary Treatment: sham-rt-fMRI-Neurofeedback
Phase:
Study Start date:
March 01, 2022
Estimated Completion Date:
June 30, 2025
Study Description
Connect with a study center
Boston VA Healthcare System, Brockton
Brockton, Massachusetts 02301
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.